-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11,...
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR);...
SARASOTA, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage...
Vanessa Tolosa joins as Senior Vice President of Research and Development; Vivek Pinto as Director of Medical AffairsNEW YORK, June...
BEIJING, June 11, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic...
Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting...
BASKING RIDGE, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
MIAMI, FL, June 11, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on...
Dan Pawliw headshot Dan Pawliw, GraceMed's new CEO TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- GraceMed, a leading consolidator in...
SMARTOX has deployed over 50 of INBS’ Intelligent Fingerprinting Drug Screening Readers and facilitated over 7,000 screening tests, including more...
Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in...
LONDON and NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Shares Expected to Begin Trading on a Split-Adjusted Basis on June 13, 2025SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE)...
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- IntelGenx, a leader in oral thin film drug delivery, today announced its official...
$2 million in DoD funding enables the evaluation of SeaStar Medical’s SCD therapy in the setting of severe burns, inhalation...
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25...
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE...
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on...